Nanoengineered Sprayable Therapy for Treating Myocardial Infarction

ACS Nano. 2022 Mar 22;16(3):3522-3537. doi: 10.1021/acsnano.1c08890. Epub 2022 Feb 14.

Abstract

We report the development, as well as the in vitro and in vivo testing, of a sprayable nanotherapeutic that uses surface engineered custom-designed multiarmed peptide grafted nanogold for on-the-spot coating of an infarcted myocardial surface. When applied to mouse hearts, 1 week after infarction, the spray-on treatment resulted in an increase in cardiac function (2.4-fold), muscle contractility, and myocardial electrical conductivity. The applied nanogold remained at the treatment site 28 days postapplication with no off-target organ infiltration. Further, the infarct size in the mice that received treatment was found to be <10% of the total left ventricle area, while the number of blood vessels, prohealing macrophages, and cardiomyocytes increased to levels comparable to that of a healthy animal. Our cumulative data suggest that the therapeutic action of our spray-on nanotherapeutic is highly effective, and in practice, its application is simpler than other regenerative approaches for treating an infarcted heart.

Keywords: cardiovascular diseases; heart muscle; myocardial infarction; nanogold; peptides.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Electric Conductivity
  • Macrophages
  • Mice
  • Myocardial Infarction* / drug therapy
  • Myocardium
  • Myocytes, Cardiac

Grants and funding